| abstract |
The present invention relates to a positive allosteric modulator (“PAM”) of a metabolically modulated glutamic acid agonistic receptor subtype 2 (“mGluR2”), or a pharmaceutically acceptable salt or solvate thereof, or a metabolically modulated glutamic acid agonistic receptor second subtype (“mGluR2”). to a combination comprising an orthosteric agonist of a subtype compound, or a pharmaceutically acceptable salt or solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand. |